GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

4D-110 overview

4D-110 is under development for the treatment of choroideremia. The therapy is administered through intravitreal route into retina. The therapy is based on vector evolution platform technology that uses AAV2 (Adeno-Associated Virus2) vector variant carrying a transgene encoding a codon-optimized human choroideremia (CHM) gene.

4D Molecular Therapeutics overview

4D Molecular Therapeutics is a gene therapy company that discovers and develops targeted and proprietary AAV gene therapy vectors and therapeutic products. The company’s pipeline products include 4D-125, 4D-110, 4D-150, 4D-135, 4D-310 and 4D-710. It has developed a technology platform, Therapeutic Vector Evolution that empowers to create customized gene delivery vehicles (novel AAV vectors) to deliver genes to any tissue or organ in the body. 4D Molecular Therapeutics develops pipeline products that targets therapeutic areas such as liver, retina, heart, brain, skeletal muscle, and lung, among others. The company works in partnership with F. Hoffmann-La Roche Ltd to design, develop and commercialize AAV products for use in ophthalmology indications. 4D Molecular Therapeutics is headquartered at Emeryville, California, the US.

For a complete picture of 4D-110’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.